ASR Nederland N.V. ASRNL

ASR Nederland has delivered a powerful share price run in recent years, which naturally raises a question for anyone looking at the stock today. Are investors now paying a level that is properly backed by the returns the insurer earns on its capital base? Over the past 5 years the ASR Nederland stock price has gained 161.5%, which puts real weight on whether current buyers are paying for capital returns the business can actually sustain. The group relies on turning collected premiums and...

ASR Nederland NV (ARNNY) recently announced a total dividend of $0.8 per share, with the ex-dividend date set for 2026-08-31. This upcoming payment includes a $0.8 per share cash dividend, payable on 2026-09-15. As investors look forward to this payment, the spotlight also shines on the company's dividend history, yield, and growth rates.

ASR Nederland NV (ASRRF) delivers a robust first half with OCC up 7% to EUR773 million and operating result up 10%, while navigating disability uncertainty and pension buyout competition.

The annual Corbion General Shareholders Meeting held on 13 May 2026 approved the appointments of Per Falholt and Bob Elfring as members of the Supervisory Board. Per Falholt brings over 40 years of experience in research and development, innovation, and leadership in the biotechnology and life sciences sectors. He currently serves as Operating Partner at Forbion and is co-founder and Chief Scientific Officer at 21st.BIO. He also holds several board positions and previously led global R&D at Novo

ASR Nederland NV (ASRRF) reports a 12% rise in operating results and a 20-point increase in solvency ratio, while announcing significant dividend growth and share buybacks.